## Lecanemab-irmb (Leqembi)

Provider Order Form rev. 01/02/2024

PATIENT INFORMATIO	N F	Referral Statu	<b>ıs:</b> □ New R	eferral   Updated C	Order
Patient Name:			DOB:	Patient F	
Patient Address:				Patient Email:	
Allergies:			□NKDA	Weight (lbs/kg):	Height (in/cm):
	Last Infusion:	Next Due D		Preferred Location	
				Treferred Location	<u>·</u>
DIAGNOSIS (Please prov	ride ICD-10 code in space p	rovided)			
Alzheimer's Disease:					
Other:	Description	1:			
THERAPY ADMINISTRA	ATION & DOSING		PRE-MEDI	CATION ORDERS	
☑ Administer Leqembi 10r		mg		500mg / □ 650mg PO	
IV every 2 weeks. Infuse in			☐ Loratadine		
☐ Flush the IV line with no				mg 🗆 PO / 🗆 IVP	
medication is infused.			☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP		
☑ Dosing Weight: kg				ol 🗆 40mg / 🗆 125mg I	
ADDITIONAL ORDERS			☐ Other:		
ADDITIONAL ONDERS			NURSING		
				ion and notify provider	
			Hold if amyloid beta pathology has not been confirmed.		
				normal vital signs brain MRI results in cha	rt (need MRI within one year
			of starting treatment, and prior to 5th, 7th, and 14t		
				usion).	and a Abrahamalities (ADIA) as
				orted on MRI results.	naging Abnormalities (ARIA) as
					e or altered mental status.
					then every 30 minutes until
			patient disch	arge	
				ursing care per Nursing F	
				vity Reaction Manageme	ent Protocol and post-
			procedure ol		
		☑ To report suspected adverse reactions, contact Biogen at 1-833-			
		425-9360 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch			
			www.fda.gov	//medwatch	
PROVIDER INFORMAT	ION				
Preferred Contact Name:		Preferred Contact Email:			
Ordering Provider:		Provider NPI:  Phone: Fax:			
Referring Practice Name: Practice Address:				State:	Zip Code:
			City:		•
REQUIRED DOCUMEN			-		
=				•	most recent OVN including
treatment failures or contra		_	= -		ratient Registry, MRI at
initial and throughout trea	intent, PET of CSF analysis	ior amylold bo	oules, cognitive	e runction score	
Provider Name (print)	Pro	Provider Signature			Date